T-cell therapy in the treatment of post-transplant lymphoproliferative disease (original) (raw)

• Gottschalk, S., Rooney, C. M. & Heslop, H. E. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 56, 29–44 (2005).
  CAS PubMed Google Scholar
• Cohen, J. I. Epstein-Barr virus infection. N. Engl. J. Med. 343, 481–492 (2000).
  CAS PubMed Google Scholar
• Hislop, A. D., Taylor, G. S., Sauce, D. & Rickinson, A. B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587–617 (2007).
  CAS PubMed Google Scholar
• Khanna, R., Moss, D. & Gandhi, M. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat. Clin. Pract. Oncol. 2, 138–149 (2005).
  CAS PubMed Google Scholar
• Heslop, H. E. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925–935 (2010).
  CAS PubMed PubMed Central Google Scholar
• Doubrovina, E. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119, 2644–2656 (2012).
  CAS PubMed PubMed Central Google Scholar
• Haque, T. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110, 1123–1131 (2007).
  CAS PubMed Google Scholar
• Long, H. M., Taylor, G. S. & Rickinson, A. B. Immune defence against EBV and EBV-associated disease. Curr. Opin. Immunol. 23, 258–264 (2011).
  CAS PubMed Google Scholar
• Babcock, G. J., Decker, L. L., Freeman, R. B. & Thorley-Lawson, D. A. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190, 567–576 (1999).
  CAS PubMed PubMed Central Google Scholar
• Thorley-Lawson, D. A., Duca, K. A. & Shapiro, M. Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality. Trends Immunol. 29, 195–201 (2008).
  CAS PubMed Google Scholar
• Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328–1337 (2004).
  CAS PubMed Google Scholar
• Abu-Elmagd, K. M. et al. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation 88, 926–934 (2009).
  PubMed Google Scholar
• Babcock, G. J., Decker, L. L., Freeman, R. B. & Thorley-Lawson, D. A. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190, 567–576 (1999).
  CAS PubMed PubMed Central Google Scholar
• Swerdlow, S. H., Webber, S. A., Chadburn, A. & Ferry, J. Post transplant lymphoproliferative disorders in Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn (eds Swerdlow, S. H., Campo, E. & Harris, N. L) 342–349 (International Agency for Research on Cancer, Lyon, 2008).
  Google Scholar
• Meij, P. et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101, 4290–4297 (2003).
  CAS PubMed Google Scholar
• Brunstein, C. G. et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108, 2874–2880 (2006).
  CAS PubMed PubMed Central Google Scholar
• Cohen, J. et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br. J. Haematol. 129, 229–239 (2005).
  PubMed Google Scholar
• Landgren, O. et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113, 4992–5001 (2009).
  CAS PubMed PubMed Central Google Scholar
• Swinnen, L. J. et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 86, 215–222 (2008).
  CAS PubMed PubMed Central Google Scholar
• Gross, T. G., Savoldo, B. & Punnett, A. Posttransplant lymphoproliferative diseases. Pediatr. Clin. North Am. 57, 481–503 (2010).
  PubMed Google Scholar
• Dotti, G. et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 69, 827–833 (2000).
  CAS PubMed Google Scholar
• Dotti, G. et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 74, 1095–1102 (2002).
  PubMed Google Scholar
• Heslop, H. E. How I treat EBV lymphoproliferation. Blood 114, 4002–4008 (2009).
  CAS PubMed PubMed Central Google Scholar
• Parker, A. et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br. J. Haematol. 149, 675–692 (2010).
  PubMed Google Scholar
• Gulley, M. L. & Tang, W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 23, 350–366 (2010).
  CAS PubMed PubMed Central Google Scholar
• Parker, A. et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br. J. Haematol. 149, 693–705 (2010).
  PubMed Google Scholar
• Styczynski, J. et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 43, 757–770 (2009).
  CAS PubMed Google Scholar
• Tomblyn, M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant. 15, 1143–1238 (2009).
  CAS PubMed PubMed Central Google Scholar
• Zelenetz, A. D. et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J. Natl Compr. Canc. Netw. 8, 288–334 (2010).
  PubMed Google Scholar
• Kuehnle, I. et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95, 1502–1505 (2000).
  CAS PubMed Google Scholar
• van Esser, J. W. et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99, 4364–4369 (2002).
  CAS PubMed Google Scholar
• Carpenter, P. A. et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99, 2712–2719 (2002).
  CAS PubMed Google Scholar
• Savoldo, B. et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am. J. Transplant. 5, 566–572 (2005).
  CAS PubMed Google Scholar
• Khanna, R. et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10391–10396 (1999).
  CAS PubMed PubMed Central Google Scholar
• Comoli, P. et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99, 2592–2598 (2002).
  CAS PubMed Google Scholar
• Savoldo, B. et al. Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108, 2942–2949 (2006).
  CAS PubMed PubMed Central Google Scholar
• Bollard, C. M. et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110, 2838–2845 (2007).
  CAS PubMed PubMed Central Google Scholar
• Thorley-Lawson, D. A. & Allday, M. J. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat. Rev. Microbiol. 6, 913–924 (2008).
  CAS PubMed Google Scholar
• Heslop, H. E., Brenner, M. K. & Rooney, C. M. Donor T-cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679–680 (1994).
  CAS PubMed Google Scholar
• O'Reilly, R. J. et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol. Rev. 157, 195–216 (1997).
  CAS PubMed Google Scholar
• Ciceri, F. et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 10, 489–500 (2009).
  PubMed Google Scholar
• Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).
  CAS PubMed PubMed Central Google Scholar
• Heslop, H. E. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925–935 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gottschalk, S. et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 97, 835–843 (2001).
  CAS PubMed Google Scholar
• Sherritt, M. A. et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75, 1556–1560 (2003).
  PubMed Google Scholar
• Peggs, K. S. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362, 1375–1377 (2003).
  PubMed Google Scholar
• Bollard, C. M. et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99, 3179–3187 (2002).
  CAS PubMed Google Scholar
• Smith, C. A. et al. Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J. Hematother. 4, 73–79 (1995).
  CAS PubMed Google Scholar
• Peggs, K. S. et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin. Infect. Dis. 52, 49–57 (2011).
  CAS PubMed Google Scholar
• Feuchtinger, T. et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116, 4360–4367 (2010).
  CAS PubMed Google Scholar
• Moosmann, A. et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115, 2960–2970 (2010).
  CAS PubMed Google Scholar
• Schmitt, A. et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51, 591–599 (2011).
  CAS PubMed Google Scholar
• Neudorfer, J. et al. Reversible HLA multimers (streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J. Immunol. Methods 320, 119–131 (2007).
  CAS PubMed Google Scholar
• Cobbold, M. et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202, 379–386 (2005).
  CAS PubMed PubMed Central Google Scholar
• Gerdemann, U. et al. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol. Ther. 17, 1616–1625 (2009).
  CAS PubMed PubMed Central Google Scholar
• Uhlin, M. et al. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol. Immunother. 59, 473–477 (2010).
  PubMed Google Scholar
• Gerdemann, U. et al. Nucleofection of DCs to generate multi virus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol. Ther. 17, 1616–1625 (2009).
  CAS PubMed PubMed Central Google Scholar
• Gerdemann, U. et al. Adoptive transfer of rapidly-generated multi virus-specific T-cells to treat adenovirus, EBV and CMV infections of hematopoietic stem cell transplant recipients [abstract]. Biol. Blood Marrow Transplant. 18, 219 (2012).
  Google Scholar
• Gerdemann, U. et al. Rapidly-generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol. Ther. (in press).
• Schmitt, A. et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51, 591–599 (2011).
  CAS PubMed Google Scholar
• Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757–768 (2004).
  CAS PubMed Google Scholar
• Burrows, S. R., Khanna, R., Burrows, J. M. & Moss, D. J. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J. Exp. Med. 179, 1155–1161 (1994).
  CAS PubMed Google Scholar
• Amir, A. L. et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115, 3146–3157 (2010).
  CAS PubMed Google Scholar
• Melenhorst, J. J. et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116, 4700–4702 (2010).
  CAS PubMed PubMed Central Google Scholar
• Haque, T. et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 72, 1399–1402 (2001).
  CAS PubMed Google Scholar
• Haque, T. et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436–442 (2002).
  PubMed Google Scholar
• Sun, Q., Burton, R., Reddy, V. & Lucas, K. G. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br. J. Haematol. 118, 799–808 (2002).
  PubMed Google Scholar
• Barker, J. N. et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116, 5045–5049 (2010).
  CAS PubMed PubMed Central Google Scholar
• Leen, A. M. et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12, 1160–1166 (2006).
  CAS PubMed Google Scholar
• Leen, A. M. et al. Most closely HLA-matched allogeneic virus specific cytotoxic T-lymphocytes (CTL) to treat persistent reactivation or infection with adenovirus, CMV and EBV after hematopoietic stem cell transplantation (HSCT) [abstract]. Blood 116 (Suppl.), a829 (2010).
  Google Scholar
• Brewin, J. et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 114, 4792–4803 (2009).
  CAS PubMed Google Scholar
• De Angelis, B. et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 114, 4784–4791 (2009).
  CAS PubMed PubMed Central Google Scholar
• Huye, L. E. et al. Combining mTOR inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol. Ther. 19, 2239–2248 (2011).
  CAS PubMed PubMed Central Google Scholar
• Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
  CAS PubMed Google Scholar
• Heslop, H. E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551–555 (1996).
  CAS PubMed Google Scholar
• Rooney, C. M. et al. Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
  CAS PubMed Google Scholar
• Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994).
  CAS PubMed Google Scholar
• Gustafsson, A. et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95, 807–814 (2000).
  CAS PubMed Google Scholar
• Lucas, K. G. et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91, 3654–3661 (1998).
  CAS PubMed Google Scholar
• Imashuku, S. et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant. 20, 337–340 (1998).
  Google Scholar
• Comoli, P. et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant. 7, 1648–1655 (2007).
  CAS PubMed Google Scholar
• Haque, T. et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J. Immunol. 160, 6204–6209 (1998).
  CAS PubMed Google Scholar
• Comoli, P. et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T-cells. Am. J. Transplant. 5, 1415–1422 (2005).
  PubMed Google Scholar
• Gandhi, M. K. et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am. J. Transplant. 7, 1293–1299 (2007).
  CAS PubMed Google Scholar